{"doi":"10.1183/13993003.00114-2025","title":"Targeting the AXL pathway: a promising strategy for pulmonary fibrosis","abstract":"<title>Extract</title> Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease characterised by the accumulation of aberrant fibrotic tissue that is irreversible and results in impaired pulmonary function and respiratory failure. Globally, IPF affects approximately 3 million individuals, with an annual incidence rate of 3–9 cases per 100 000 people in North America and Europe [1]. Median survival following diagnosis is estimated to be between 3 and 5 years, with a 5-year survival rate comparable to that of many aggressive malignancies [2]. Significant advancements in the management of IPF have been made with the development of antifibrotic therapies that slow disease progression. Of the approved therapies, nintedanib is a tyrosine kinase inhibitor that targets multiple receptors, including vascular endothelial growth factor, fibroblast growth factors and platelet-derived growth factor [3]. Given the central role of receptor tyrosine kinases (RTKs) within IPF, there is growing interest in their potential to understand the mechanisms underlying disease progression and inform targeted therapeutic strategies.","journal":"European Respiratory Journal","year":2025,"id":544628,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9572,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":381133,"name":"A. Brent Carter","orcid":"0000-0001-6002-4715","position":1,"is_corresponding":false},{"id":244715,"name":"Jennifer L. Larson‐Casey","orcid":"0000-0001-7238-7986","position":0,"is_corresponding":true}],"reference_count":25,"raw_metadata":null,"created_at":"2026-07-19T02:53:12.864581Z","pmid":"40473304","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}